| Pharmaceutical Information |
| Drug Name |
Eculizumab |
| Drug ID |
BADD_D00742 |
| Description |
Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246]
Eculizumab was granted FDA approval on 16 March 2007.[L6919] |
| Indications and Usage |
Eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy[L6919,A2246], and neuromyelitis optica spectrum disorder (NMOSD).[L6916] |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA25 |
| DrugBank ID |
DB01257
|
| KEGG ID |
D03940
|
| MeSH ID |
C481642
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D01RQV
|
| NDC Product Code |
69438-0001; 25682-001; 68225-042; 42098-0005 |
| UNII |
A3ULP0F556
|
| Synonyms |
eculizumab | 5G1.1 | H5G1.1VHC+H5G1.1VLC | H5G1.1 | H5G1-1 | H5G11 | Elizaria | Soliris | Alexion |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
219685-50-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
